| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.68 | 0.3 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.064 | 0.3 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |